VCA Inc. & Abaxis, Inc. Announce Long-Term Product Supply Agreement & a Co-Marketing Agreement for Laboratory Services, VetSc...
13 5월 2014 - 7:34AM
Business Wire
VCA Inc. (Nasdaq: WOOF), a leading animal healthcare company in
the United States and Canada, and Abaxis, Inc. (Nasdaq: ABAX), a
medical products company manufacturing point-of-care blood analysis
systems, today jointly announced they have entered into two
long-term agreements, the first a long-term product supply
agreement for VCA’s Animal Hospitals and the second a co-marketing
agreement with VCA’s Antech Diagnostic reference laboratories.
Under the long-term product supply agreement VCA will purchase
VetScan VS2 chemistry analyzers and diagnostic reagent discs from
Abaxis for placement in the majority of VCA’s more than 600 animal
hospitals located in North America.
Additionally, VCA and Abaxis have entered into a non-exclusive
co-marketing relationship to capitalize on new growth opportunities
within the animal healthcare industry. Representatives from Abaxis
and Antech Diagnostics will work together in providing complete
state-of-the-art diagnostic solutions to better offer veterinary
practices throughout North America the ability to combine Antech
Diagnostic laboratory services with the use of VetScan VS2
chemistry analyzers.
Bob Antin, chairman, president and chief executive officer of
VCA, commented, “We are excited by the greater access our
veterinarians will now have to Abaxis’ state-of-the-art diagnostic
technology as we work towards our core mission of providing quality
veterinary care to our patients and peace of mind for our pet owner
clients.
“We also see great potential benefit in strengthening the
relationship between two demonstrated leaders in veterinary
diagnostics by joining the sales and marketing capabilities of
Antech Diagnostics and Abaxis. We are confident that this
relationship will further the goals of both companies in providing
a comprehensive suite of diagnostic solutions to the veterinary
community. We look forward to working with Abaxis for many years to
come.”
Clint Severson, chairman, president and chief executive officer
of Abaxis, said, “We are pleased to be entering into this long-term
supply agreement with VCA. As the leader in the veterinary hospital
industry VCA enjoys a well-deserved reputation of providing
compassionate care and delivering excellent patient outcomes for
pet owners throughout the United States. We are pleased to provide
VCA Animal Hospitals the leading-edge diagnostic technology to
enhance their ability to provide patient care on an even more
timely and cost-effective manner.”
Mr. Severson added, “This co-marketing agreement with Antech
Diagnostics creates new and exciting opportunities for in-house
testing and reference laboratory services that can now be utilized
by any type of veterinary practice, be it single doctor,
multi-doctor or specialty practice. Working together, both
companies are now better positioned to generate incremental new
business and to expand market share in their respective markets. We
believe this will be a mutually beneficial agreement for the next
decade and we are excited with the possibilities ahead.”
About VCA/Antech Diagnostics
VCA owns, operates and manages the largest networks of
freestanding veterinary hospitals and veterinary-exclusive clinical
laboratories in the country, is the largest provider of online
communication, professional education and marketing solutions to
the veterinary community, and supplies diagnostic imaging equipment
to the veterinary industry. For further information on VCA, visit
its website at www.vcaantech.com.
Antech Diagnostic services more than 16,000 animal hospitals
throughout North America through its network of more than 50
reference laboratories in the United States and Canada. Antech
Diagnostic offers over 300 different tests in chemistry, pathology,
endocrinology, serology, hematology, and microbiology and provides
its clients with expert telemedicine with access to more than 400
board-certified specialists 24/7. For further information on Antech
Diagnostics, visit its website at www.antechdiagnostics.com.
About Abaxis
Abaxis develops, manufactures, markets and sells portable blood
analysis systems for use in any veterinary or human patient-care
setting to provide clinicians with rapid blood constituent
measurements. The system consists of a compact, 5.1 kilogram (11.2
pounds), portable analyzer and a series of single-use plastic
discs, called reagent discs that contain all the chemicals required
to perform a panel of up to 13 tests on veterinary patients and 14
tests on human patients. The system can be operated with minimal
training and performs multiple routine tests on whole blood, serum
or plasma samples. The system provides test results in less than 12
minutes with the precision and accuracy equivalent to a clinical
laboratory analyzer. The veterinary business also provides to the
animal health and research market a line of hematology instruments
for point-of-care complete blood counts (CBC), a specialty
instrument to screen for and detect clotting disorders and to
measure equine fibrinogen levels, a handheld instrument for the
rapid assessment of certain critical care tests and rapid
point-of-care tests for Heartworm infections, Parvovirus, Giardia
and Lyme disease. For more information, visit
http://www.abaxis.com.
Forward-Looking Statements
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Among the forward-looking statements in this press release
are statements addressing our future plans or expectations, future
product offerings and results of operation. These forward-looking
statements are not historical facts and are inherently uncertain
and out of our control. Any or all of our forward-looking
statements in this press release may turn out to be wrong. They can
be affected by inaccurate assumptions we might make or by known or
unknown risks and uncertainties. Actual future results may vary
materially. Among other factors that could cause our actual results
to differ from this forward-looking information are: the continued
effects of the economic uncertainty prevailing in regions in which
we operate; our ability to execute on our growth strategy and to
manage acquired operations; changes in demand for our products and
services; fluctuations in our revenue adversely affecting our gross
profit, operating income and margins; and the effects of the other
factors discussed in our Annual Report on Form 10-K, Reports on
Form 10-Q and our other filings with the SEC.
VCA Antech, Inc.Tomas W. FullerChief Financial
Officer310-571-6505
Abaxis, Inc. (delisted) (NASDAQ:ABAX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Abaxis, Inc. (delisted) (NASDAQ:ABAX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024